Marker Therapeutics Reports Increased R&D Expenses Amid Revenue Decline

Marker Therapeutics ( (MRKR) ) has released its Q2 earnings. Here is a breakdown of the information Marker Therapeutics presented to its investors.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of novel T cell-based immunotherapies for treating hematological malignancies and solid tumors. The company’s technology focuses on the selective expansion of non-engineered, tumor-specific T cells to produce a broad spectrum anti-tumor activity.

Marker Therapeutics recently released its earnings report for the quarter ending June 30, 2025. The company reported a net loss of $4.02 million for the quarter, reflecting an increase in operating expenses primarily driven by research and development activities.

The company’s revenue for the quarter was $861,184, a decrease from the previous year’s $1.17 million. This decline was mainly due to reduced grant income. Despite the revenue drop, Marker Therapeutics continued to invest heavily in research and development, with expenses rising to $4.18 million compared to $2.34 million in the same period last year. The company also reported a significant increase in the number of common shares outstanding, which rose to 11.3 million from 10.7 million at the end of 2024.

Looking ahead, Marker Therapeutics remains focused on advancing its clinical programs, particularly the MT-601 therapy for lymphoma. The company has secured several grants to support its research and development efforts, which are expected to provide financial stability in the near term. Management anticipates that the current cash reserves, along with anticipated grant income, will fund operations into the second quarter of 2026.

Overall, while Marker Therapeutics faces challenges due to ongoing losses and increased expenses, the company is strategically positioned to advance its clinical pipeline and leverage grant funding to support its operations.